The medical community is grappling with unexpected results after a promising attempt to curb cardiovascular disease through genetic targeting fell short. For years, researchers have focused on lipoprotein(a), a specific particle that affects roughly twenty percent of the population and significantly increases the likelihood of heart attacks and strokes. While scientists believed lowering these levels would translate directly into saved lives, recent data suggests the connection may be more complex than previously thought.
Details from the Phase 3 HORIZON trial, funded by Novartis, were released during the American Heart Association’s scientific sessions and published in the New England Journal of Medicine. The experimental drug known as pelacarsen succeeded in its primary biological goal, drastically reducing the amount of lipoprotein(a) circulating in patients’ blood. However, this biochemical success did not lead to clinical victory. After nearly five years of monitoring, there was no significant difference between those taking the medication and those receiving a placebo regarding deaths or major cardiac events.
These findings cast a shadow over current strategies for treating genetically driven heart risks. Because pelacarsen effectively cleared the targeted particles without preventing strokes or heart attacks, experts are now questioning whether simply lowering lipoprotein(a) is enough to change a patient’s destiny. This failure forces pharmaceutical developers and cardiologists to rethink their approach to preventative care for high risk individuals who do not respond to traditional cholesterol treatments.
